Polaryx Therapeutics said its shares will start trading on the Nasdaq Capital Market on Monday under the "PLYX" symbol.
The clinical-stage biotech firm said it is developing therapies for rare orphan lysosomal storage disorders.
Maxim Group acted as the financial advisor to the company for the direct listing, the firm said.